Sartorius Stedim Biotech(SSB) launches new BIOSTAT STR? Bioreactor series

【 China chemical network instrument Dynamic 】 gottingen in Germany known | French President Obama, April 27, 2017 -- Sartorius Stedim Biotech (SSB), a leading international supplier to the biopharmaceutical industry, announced the launch of its next-generation BIOSTAT STR® bioreactor family -- based on a conventional stirred tank design. Fully scalable disposable bioreactor. With upgraded hardware, software, and a fully integrated new Flexsafe STR® disposable bioprocess bag, the new bioreactor family enables rapid and easy process scaling for biologics and vaccines.

The BIOSTAT STR® biorereactor is equipped with an improved stainless steel bag-body scaffold for easy installation of single-use Flexsafe STR® bioprocess bags. The bioreactor family consists of five systems of different sizes, providing working volumes from 12.5 L litres to 2,000 L. Because the bioreactor has the same geometric design as SSB's AMBR ® 250 micro bioreactor, it has become the industry's gold standard for scaling down and linear scaling up. Using this innovative technology platform, process transfer from 250 mL to 2,000 L can be achieved in a matter of weeks instead of months.

The new bioreactor is a perfect match for the new disposable Flexsafe STR® bioprocess bag. The bioprocess bag features an advanced disposable sensor solution and is made from patented multilayer S80 polyethylene film for durability. The resin and additive formulations used in membrane manufacturing have been fully characterized, and the extrusion process parameters have been controlled within defined ranges, and the extracts and extracts have excellent inter-batch consistency. Fully independent design of the new bioreacter and disposable bioprocess bag prevents cross-contamination of products and saves time in assembly, validation, online cleaning and online sterilization operations.

In addition to being equipped with the highest purity process bag, the system is designed for efficient oxygen supply, mixing and carbon dioxide removal. These combined characteristics ensure excellent cell culture performance and reproducible high density growth even for sensitive cell lines. BIOSTAT STR® bioreactersare therefore ideal for situations where very high cell densities are required in a continuous process, or where vaccines and recombinant proteins are produced safely in a cGMP environment.

The connectivity of the next-generation bioreactor software system can be upgraded to integrate control through BioPAT® MFCS software or commonly used third-party distributed control systems (DCS) for industrial use, such as Emerson DeltaV® or Siemens SIMATIC PCS7; This provides greater flexibility in process control and data acquisition for bioprocesses. "Direct linear scale-up is essential to ensure the efficiency and cost-effectiveness of bioprocess development," says Thorsten Adams, PhD, Product Management Director, Fermentation Technologies at Sardoris Stedi. Our next-generation BIOSTAT STR® biorereactor, combined with AMBR ®250 technology, will help significantly reduce process development time compared to traditional stainless steel containers. "These highly scalable, single-use bioreactors are an intelligent, low-risk bioprocess development solution for multi-product manufacturers and CMO organizations for biologics and vaccines."

Understand the SSB is a new generation BIOSTAT STR ® bioreactor and new Flexsafe STR ® biotechnology bags for more information, please visit: www.sartorius.com/biostat-str and www.connect-upstream.com/zh

About Sartorius Stati

Sartorius Stedim Biotech is a leading international provider of equipment and services for the biopharmaceutical industry, providing safe, timely and cost-effective integrated solutions for biopharmaceutical development and manufacturing worldwide. As a supplier of complete solutions, Sartorius Stati offers a portfolio of products covering almost every step of the biopharmaceutical process. The company is committed to promoting disposable technology and value-added services to meet the rapidly developing technology needs of the biopharmaceutical industry. Headquartered in Aubanne, France, the company is listed on the Euronext in Paris. It is well known for its manufacturing and r&d centers in Europe, North America and Asia and its worldwide sales network.